Serrapeptase

Serrapeptase is a serine protease originally isolated from the non-pathogenic bacterium Serratia marcescens found in the gut of the silkworm, and has been used as an anti-inflammatory enzyme supplement, particularly in Europe and Japan. Its proposed mechanisms include fibrinolysis (breakdown of fibrin clots and scar tissue), reduction of bradykinin-mediated inflammation, and thinning of mucus secretions, making it theoretically useful for post-surgical swelling, sinusitis, and carpal tunnel syndrome. Human clinical trials exist but are generally small and methodologically limited; a 2013 Cochrane-adjacent systematic review found insufficient evidence to support clinical use for most claimed indications. Oral bioavailability is a significant pharmacokinetic concern — whether intact enzymatic activity survives gastric transit is debated, and enteric-coated formulations are typically recommended to protect the enzyme from acid degradation.

Evidence last reviewed: 05 Apr 2026